Melinta Therapeutics reports the successful completion of a $67 million Series 4 equity financing. Malin Corporation plc led the round and was joined by other existing investors, including Vatera Healthcare Partners.

“Melinta has developed a novel multi-product portfolio, including the advancement of delafloxacin through its first Phase 3 ABSSSI trial, presenting the type of compelling investment that our firm seeks to be a part of,” said Sean Murphy, Malin Corporation plc Board Director and appointee to the Melinta Board. “With a proven management team that has outstanding experience commercializing anti-infective therapies for underserved patient populations, Melinta is poised for success.”